Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective study by Alonso, Alvaro et al.
RESEARCH ARTICLE Open Access
Association of smoking with amyotrophic lateral
sclerosis risk and survival in men and women: a
prospective study
Alvaro Alonso
1,2*, Giancarlo Logroscino
3, Susan S Jick
4, Miguel A Hernán
5,6
Abstract
Background: Previous epidemiologic studies have examined the association of smoking with amyotrophic lateral
sclerosis (ALS) incidence, but their results have been inconsistent. Moreover, limited information exists on the
association between smoking and survival in ALS patients. We evaluated the association of smoking with ALS
incidence and survival in a population-based cohort.
Methods: We conducted a case-control study nested in the General Practice Research Database, a computerized
clinical database in the United Kingdom. Cases were 1143 individuals with a diagnosis of ALS; 11,371 matched
controls were selected among GPRD participants free of ALS. Predictors of survival were determined in the ALS
cases. Smoking information was obtained from the computer database.
Results: Smoking was not associated with the risk of ALS in this population. The rate ratio (RR) of ALS comparing
ever versus never smokers was 1.04, 95% confidence interval (CI) 0.80-1.34. In analysis stratified by gender, however,
ever smoking was associated with ALS in women (RR 1.53, 95% CI 1.04-2.23) but not in men (RR 0.75, 95% CI 0.53-
1.06). Mortality was 71% after 2.1 average years of follow-up. Old age and female sex were associated with lower
survival. Smoking was a predictor of mortality only in women. Comparing ever versus never smokers, RR (95% CI)
of death was 1.31 (1.04-1.65) in women, and 0.90 (0.72-1.11) in men.
Conclusion: In this large population-based study, smoking was associated with ALS risk and worse survival in
women but not in men.
Background
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease characterized by the progressive loss of
upper and lower motor neurons. Although its etiology
remains unknown, certain environmental (non-genetic)
factors have been postulated as potential causative fac-
tors[1]. Cigarette smoking, in particular, has attracted
interest as a risk factor for ALS. Smoking could increase
the risk of ALS through several mechanisms, including
inflammation, oxidative stress, and neurotoxicity caused
by heavy metals and other chemical compounds present
in cigarette smoke[2-5].
A number of epidemiologic studies have assessed the
association of cigarette smoking with ALS incidence, but
their results have been inconsistent[6]. More recently, a
systematic review and meta-analysis has suggested that
sex could modify the association between smoking and
ALS risk, with smoking linked to higher risk of ALS in
women but not in men[7]. Similarly, the only three stu-
dies that estimated the association of smoking with the
survival of ALS patients were inconclusive[8-10].
Here we present estimates of the association of smok-
ing with ALS risk, and with survival in ALS patients, in
the General Practice Research Database (GPRD), a large
clinical database in the United Kingdom (UK).
Methods
Study population
The GPRD has been described in detail elsewhere
[11,12]. Briefly, starting in 1987, selected general practi-
tioners in the UK agreed to record electronically their
patients’ clinical information and provide these
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mation includes demographic variables, symptoms, life-
styles, such as smoking, clinical variables, such as body
mass index, medical diagnoses, drug prescriptions, refer-
rals to and diagnosis from specialists, and hospital
admissions. Medical records, including hospital dis-
charge and referral letters, are available for review upon
request. Since its inception, more than 5 million UK
residents have been included in the database. The
GPRD population is representative of the British popula-
tion with regard to age, gender, and geographic distribu-
tion[12]. Additionally, different validation studies have
shown that data contained in the GPRD is of enough
quality and completeness to be used for epidemiologic
analysis[13-16].
The GPRD is managed by the Medicines and Health-
care Products Regulatory Agency in the UK. The pre-
sent study has been approved by the Institutional
Review Board at the University of Minnesota.
ALS ascertainment
Cases of ALS were identified from the population of
patients older than age 20 enrolled in the GPRD for at
least two years from January 1990 to July 2008. Any par-
ticipant with a computer diagnosis of motor neuron dis-
ease, ALS, progressive muscular atrophy, progressive
bulbar palsy, or primary lateral sclerosis was considered
a case. In a review of medical charts and death certifi-
cates of 65 potential ALS cases identified following this
approach, we were able to confirm 85% of them[17].
Similarly, incidence rates of computer-diagnosed ALS in
the GPRD were comparable to those found in popula-
tion-based registries in Scotland and Ireland[17].
Study design
To estimate the association of smoking with ALS risk,
we conducted a nested case-control study. Cases were
individuals with ALS with at least two years of follow-
up before the date of diagnosis. Up to 10 controls free
of ALS were selected for each case matched by age (± 3
years), gender, practice, and year of enrolment in the
GPRD. Controls had to be alive and free of ALS at the
date of diagnosis of their corresponding case (index
date).
The association of smoking with ALS survival was
assessed using a cohort design. Follow-up started on the
date of diagnosis and continued until the patient died,
transferred out to a different practice, or the end of July
2008, whichever occurred earlier.
Exposure assessment
Information on smoking status before the index date
was obtained from the computer database using the ear-
liest smoking information for each study participant.
Individuals were classified as never, past, or current
smokers, or as having missing information. Detailed
information on amount of smoking was not available
but, as a surrogate marker of smoking intensity, we col-
lected information on smoking cessation advice or treat-
ment, and whether participants were labeled as ‘heavy
smokers’. In a previous publication, smokers receiving
advice or treatment had a higher risk of lung cancer
than other smokers, supporting the validity of this clas-
sification[18]. If a smoker in our population received
smoking cessation advice or treatment, or was labeled as
‘heavy smoker’, we considered him or her to be a heavy
smoker, and a non-heavy smoker otherwise. In the sam-
ple of controls, heavy smokers had a higher mortality
than non-heavy smokers, and the non-heavy smokers
had a higher mortality than never smokers, supporting
the validity of our smoking classification: in an analysis
adjusted for age and sex, the mortality rate ratio (RR)
was 2.19 (95% confidence interval [CI] 1.71-2.80) in
heavy smokers and 1.17 (95% CI 1.05-1.30) in non-
heavy smokers compared to never smokers. Addition-
ally, we obtained information on body mass index from
the database. Information on smoking was missing in
18% of the study sample (19% in men and 17% in
women).
Statistical analysis
In the case-control study, we estimated the RR of ALS
for smoking status, with never smokers as the reference
group, via conditional logistic regression models
adjusted for matching factors. The main analysis
included all cases and their respective controls. We per-
formed an additional analysis including only individuals
with at least 5 years of recorded medical information
before their index date. For this analysis, we advanced
the index date by 5 years and only used smoking infor-
mation recorded before this earlier date.
In the cohort study we estimated the mortality RR for
smoking status via a Cox proportional hazards model
with days from diagnosis to end of follow-up, as the
time variable. In addition to smoking status, we included
in the model the following variables: age at diagnosis,
gender, diagnostic classification (ALS/motor neuron dis-
ease vs. ALS variants), and calendar year. Information
on site of ALS onset was not available. Calendar year
was modeled fitting a restricted cubic spline function
with 3 knots. We excluded 12 cases in which date of
diagnosis was the same as date of death. An additional
analysis was conducted excluding individuals diagnosed
with ALS variants. Adjusted survival was estimated in
four groups defined by gender and smoking status (ever,
never) averaging survival curves for each individual in
the sample, using a SAS macro developed by Zhang et
al.[19]
In both the case-control and cohort analyses, we esti-
mated separate RR in men and women, and assessed
their heterogeneity using the likelihood ratio test.
Finally, we repeated all analyses including only
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since ALS diagnosis in older individuals is less certain.
Results
During the study period, we identified 1143 ALS cases
with at least two years of follow-up before their diagno-
sis, and selected 11,371 matched controls. Characteris-
tics of cases and controls are presented in table 1. The
median age in both groups was 67.
The association of smoking with ALS risk is presented
in table 2. Compared with never smokers, the RR (95%
CI) of ALS for ever smokers was 1.04 (0.80-1.34). The
corresponding RR (95% CI) was 1.53 (1.04-2.23) in
women and 0.75 (0.53-1.06) in men. This gender differ-
ence was present in young and older individuals. In
those older than 50, the RR (95% CI) of ALS for ever
smokers compared with never smokers was 0.74 (0.51-
1.07) in men and 1.49 (1.00-2.22) in women. In those 50
and younger, the RR (95% CI) were 0.84 (0.33-2.19) in
men and 2.14 (0.51-9.04) in women.
Results were similar when we included only cases and
controls with at least five years of follow-up before their
index date (table 2), when we adjusted for body mass
index (data not shown), and when we excluded indivi-
duals older than 75 on the index date: the RR (95% CI)
was 0.77 (0.52-1.15) in men and 1.50 (0.96-2.35) in
w o m e n .T h eR R so fA L Sf o rh e a v ys m o k e r sa n dn o n -
heavy smokers were of similar magnitude compared
with never smokers. The RR (95% CI) of ALS in heavy
smokers compared with never smokers was 1.08 (0.74-
1.56) in the entire cohort, 0.72 (0.44-1.19) in men and
1.77 (1.02-3.09) in women. The corresponding figures
comparing non heavy smokers with never smokers were
1.03 (0.80-1.33), 0.75 (0.53-1.06) and 1.50 (1.02-2.21).
Of 1131 ALS cases with at least one day of follow-up
after their diagnosis, 802 (70.9%) died, 108 (9.6%) trans-
ferred out, and 221 (19.5%) were alive at the time of last
recording in the GPRD, after an average follow-up of
2.1 years. Median survival after diagnosis was 1.5 years.
Old age and female gender were strongly associated
with mortality. Each 5-year increment in age was asso-
ciated with 20% higher mortality rate (RR 1.20, 95% CI,
1.16-1.24). Similarly, women had a 22% higher mortality
than men (RR 1.22, 95% CI, 1.06-1.41). Compared with
never smokers, the mortality RR (95% CI) was 1.45
(1.03-2.03) for heavy smokers and close to 1 for all
other groups (table 3). Compared with never smokers,
the mortality RR (95% CI) for ever smokers was 1.31
(1.04-1.65) in women and 0.90 (0.72-1.11) in men. The
risk was particularly elevated in female heavy smokers
(HR 1.94, 95% CI 1.24-3.06). As shown in figure 1,
adjusted survival was lower in women who were ever
smokers compared to men and women never smokers.
Results were similar when we excluded individuals diag-
nosed with an ALS variant.
Discussion
In this large prospective study, smoking was a predictor
or ALS in women, and of mortality in female ALS
patients, but not in men.
Smoking has been associated with several neurodegen-
erative disorders. Prospective investigations have found
a higher risk of dementia and a lower risk of Parkinson’s
disease in smokers compared to non-smokers[20,21].
The epidemiologic evidence regarding smoking and ALS
is less consistent, with some studies showing a higher
risk of ALS among smokers,[22-24] and others not find-
ing any clear association[25]. Notably, in the Cancer
Prevention Study II cohort, a prospective cohort includ-
ing over 1 million people, results were similar to ours:
ever smoking was associated with a higher risk of ALS
Table 1 Characteristics of amyotrophic lateral sclerosis
(ALS) cases and controls, General Practice Research
Database, 1990-2008
ALS
cases
Controls
N 1143 11,371
Age at index date, years 67.4
(12.5)
67.1
(12.5)
Range 23-95 20-97
Gender [% women] 44.8 44.9
Smoking [%]
Never 33.0 32.7
Missing 16.7 18.0
Ever 50.3 49.4
Former 23.9 23.7
Current 26.4 25.7
Non-heavy smokers 45.1 44.5
Heavy smokers 5.2 4.9
Body mass index, kg/m
2 [%] *
<20 3.6 3.2
20-24.9 33.1 30.1
25-29.9 29.5 30.7
≥30 9.5 11.9
Missing 24.3 24.2
Time between first smoking assessment and
index date, years
14.1 (9.4) 14.0 (9.2)
Diagnosis [%]
ALS/MND 88.6
PBP 8.8
PMA 1.4
PLS 1.2
Follow-up after diagnosis, years 2.1 (2.7)
Numbers refer to percentages or means (standard deviation).
* Corresponding to first recording of body mass index in the GPRD (average
8.3 years before index date)
ALS: amyotrophic lateral sclerosis; MND: motor neuron disease; PBP:
progressive bulbar palsy; PLS: primary lateral sclerosis; PMA: progressive
muscular atrophy
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with a lower risk in men (HR 0.77, 95% CI 0.59-1.00)
[26]. Consistent with this observation, a recent systema-
tic review and meta-analysis showed that the proportion
o fm e na n dw o m e ni nap a r t i c u l a rs t u d ym a d eam a j o r
contribution to between-study heterogeneity[7]. The
estimated pooled RR of ALS in ever versus never smo-
kers was 0.87 (95% CI 0.71-1.06) in men, and 1.58 (95%
CI 1.21-2.08) in women[7]. Results from the GPRD are
in agreement with the previous meta-analysis and rein-
force its conclusions.
Smoking could increase the risk of ALS through dif-
ferent mechanisms. Strong evidence supports the role of
smoking as a cause of oxidative damage,[2] and oxida-
tive damage has been involved in the pathogenesis of
ALS[27]. Also, more than 4 thousand different
Table 2 Rate ratios (RR) and 95% confidence intervals (CI) of amyotrophic lateral sclerosis (ALS) by smoking status
before the onset of ALS, General Practice Research Database (GPRD), 1990-2008
ALS cases Controls RR (95% CI) * RR (95% CI)**
Entire sample
Never 377 (33.0) 3714 (32.7) 1.00 (ref.) 1.00 (ref.)
Ever 575 (50.3) 5615 (49.4) 1.04 (0.80-1.34) 1.09 (0.81-1.46)
Former 273 (23.9) 2696 (23.7) 1.01 (0.74-1.39) 1.15 (0.80-1.64)
Current 302 (26.4) 2919 (25.7) 1.06 (0.79-1.41) 1.04 (0.74-1.47)
Missing 191 (16.7) 2042 (18.0) 0.88 (0.68-1.14) 0.94 (0.69-1.26)
Men
Never 207 (32.8) 1896 (30.3) 1.00 (ref.) 1.00 (ref.)
Ever 318 (50.4) 3180 (50.8) 0.75 (0.53-1.06) 0.75 (0.50-1.11)
Former 157 (24.9) 1584 (25.3) 0.73 (0.48-1.11) 0.70 (0.43-1.14)
Current 161 (25.5) 1596 (25.5) 0.76 (0.52-1.13) 0.79 (0.50-1.24)
Missing 106 (16.8) 1191 (19.0) 0.64 (0.44-0.92) 0.67 (0.44-1.02)
Women
Never 170 (33.2) 1818 (35.6) 1.00 (ref.) 1.00 (ref.)
Ever 257 (50.2) 2435 (47.7) 1.53 (1.04-2.23) 1.68 (1.08-2.61)
Former 116 (22.7) 1112 (21.8) 1.49 (0.92-2.43) 2.06 (1.20-3.53)
Current 141 (27.5) 1323 (25.9) 1.55 (1.01-2.38) 1.41 (0.84-2.36)
Missing 85 (16.6) 851 (16.7) 1.25 (0.85-1.82) 1.33 (0.86-2.04)
P interaction 0.01 0.02
* Conditional logistic regression model adjusted for age, gender, practice, and time since enrolment in the GPRD.
** Results advancing five years index date (910 cases and 9058 controls). Conditional logistic regression model adjusted for age, gender, practice, and time since
enrolment in the GPRD.
Figure 1 Estimated probability of survival after diagnosis of amyotrophic lateral sclerosis (ALS) by gender and smoking status after
standardizing for age, diagnosis (ALS vs. ALS-variants) and year of diagnosis, General Practice Research Database, 1990-2008.
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ette smoke, including heavy metals, such as lead or cad-
mium, and formaldehyde[28]. Although the role of these
in ALS pathogenesis has not been defined, some studies
point to an increased risk of ALS and worse ALS survi-
val associated with higher levels of lead exposure,[8,29]
and to a potential higher incidence of ALS in individuals
exposed to formaldehyde[30]. Systemic inflammation,
another well-known effect of smoking, might also be
involved[4]. Biological mechanisms supporting the dif-
ference in the associationo fs m o k i n gw i t hA L Si nt h e
two genders are less clear, though prior observations
suggest that women could be more sensitive to deleter-
ious effects of cigarette smoking, probably through dif-
ferences in the metabolism of tobacco compounds
[31,32]. Additional evidence suggests that the association
of smoking with different health outcomes, including
lung disease or thyroid disorders, might differ by gender
[32,33].
More intriguing is the sex difference in the association
of smoking with survival. Only three previous studies
have reported associations of smoking with ALS
prognosis. Kamel et al studied the association of differ-
ent exposures, including smoking, with survival in a
group of 100 ALS cases in New England. In age and
sex-adjusted analysis, ever smokers had a better survival
than never smokers (HR 0.6, 95% CI 0.4-1.0, with time
from diagnosis to death as the outcome, or HR 0.7, 95%
CI 0.5-1.2, with time from onset of symptoms to death
as outcome)[8]. In a report including 180 ALS patients
from Washington State, smoking did not predict mortal-
ity: compared to never smokers, the HR of death in cur-
rent smokers was 1.1 (95% 0.7-1.6) and 1.0 (95% CI 0.7-
1.4) in past smokers[9]. Neither study assessed the asso-
ciation separately in men and women. Finally, smoking
was not a significant predictor of survival in a group of
2069 ALS patients receiving riluzole in France, but the
actual estimates of association were not reported[10].
Strengths of our study include the large sample size,
providing enough statistical power for subgroup analysis,
and the selection of cases and controls from a well-
defined cohort, reducing the possibility of selection bias.
Several limitations, however, might reduce the validity
of our results. First, we have not confirmed all ALS
cases identified in the GPRD, though a previous study
suggested acceptable validity of the computer diagnosis
[17]. Because validity of ALS diagnosis could be lower
in older individuals,[34] we repeated analyses after
excluding those older than 75, obtaining similar results.
Second, smoking status was classified in broad cate-
gories (never, non-heavy smokers, heavy smokers,
unknown). Thus, we were not able to determine precise
dose-response relationships. Lastly, unmeasured con-
founding could explain our results if a risk factor for
ALS was associated with smoking and distributed
unevenly in men and women.
Conclusions
We have found that smoking is associated with higher
risk of ALS and worse survival in women but not in
men. Future studies should focus on exploring the
mechanisms that might explain the observed
associations.
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